Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-1469-0239 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Second/Third-Line Therapie nach Versagen von Docetaxel bei metastasiertem Prostatakarzinom (mCRPC)].
Aktuelle Urol
August 2021
Organgruppensprecher der Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e. V., Kuno-Fischer-Str. 8, 14057 Berlin.
[Not Available].
Aktuelle Urol
June 2021
Organgruppensprecher der Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e. V., Kuno-Fischer-Str. 8, 14057 Berlin.
[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Aktuelle Urol
March 2010
Urologie Pasing, München, Germany.
Introduction: Until recently, the standard therapy for metastatic renal cell carcinoma (mRCC) in Germany consisted of interleukin-2 (IL-2), interferon-alfa (IFN) as single agents or in combination, with or without chemotherapy. Since 2005, new drugs (target drugs) in the therapy for mRCC are available. The aim of this study was to analyse the current therapy standard in Germany.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!